Table 2.
Summary of the common drug interactions between supportive care and anticancer agents in pediatric oncology and recommendations for alternative agents
| Supportive Care Agent | Chemotherapy Agent | Outcome and Mechanism of Interaction | Alternatives | Ref |
|---|---|---|---|---|
| Phenytoin, Carbamazepine, Phenobarbital, | Anthracyclines, Cyclophosphamide, Ifosfamide, Epipodophyllotoxins, Tyrosine kinase inhibitors, Vinca alkaloids | Decreased effectiveness of chemotherapy agent through induction of CYP450 that catabolize anticancer agents | Use non-enzyme inducing anticonvulsants | 19–22 |
| Valproic acid (VPA) | Cisplatin | Increased cisplatin hematologic toxicity | - Use non-enzyme inhibiting anticonvulsants | 23,24 |
| Methotrexate | Decreased absorption of VPA | - Monitor valproic acid serum concentration | 23 | |
| Aprepitant | Anthracyclines, Epipodophyllotoxins, Cyclophosphamide, Ifosfamide, Dexamethasone, Tyrosine kinase inhibitors,Thiotepa | Increased toxicity of the chemotherapy agent through CYP450 inhibition | Use alternative antiemetic | 26,27,29 |
| Proton pump inhibitors | Methotrexate | Decreased methotrexate excretion via transporter inhibition | - Use ranitidine or sucralfate | 37 |
| Tyrosine kinase inhibitors (except imatinib) | Decreased absorption of the chemotherapy agent by decreasing gastric pH | - Separate drug administration by 3–4 hours | 47 | |
| Azole antifungals | Anthracyclines, Busulfan, Calcineurin inhibitors, Epipodophyllotoxins, Tyrosine kinase inhibitors, Vinca alkaloids | Increased toxicity through inhibition of CYP450 catabolism of active anticancer drugs | Use echinocandin antifungals or amphotericin B formulations | 12,48–51,62 |
| Amphotericin B | Cisplatin, High-dose methotrexate | Decreased excretion of renally cleared anticancer drug due to amphotericin nephrotoxicity | Use echinocandin antifungals | 56 |
| Penicillins | Methotrexate | Interference with tubular excretion of methotrexate | Consider an alternative non-penicillin antibiotic | 43,57 |
| TMP/SMX | Methotrexate | Delayed clearance of methotrexate | Some institutions hold TMP/SMX; others do not | 59,60 |
| NSAIDs | Methotrexate | Decreased excretion of methotrexate | Avoid NSAIDs, use opioids for pain if needed | 42,63,64 |
| Acyclovir (high dose) | Cisplatin, High-dose methotrexate | Additive nephrotoxicity | Do not combine if possible | 41 |
| Sargramostim, filgrastim | Vinca alkaloids | Severe atypical neuropathy | Some institutions hold factor support; others do | 65 |
| St. John’s Wort | Anthracyclines, Calcineurin inhibitors, Epipodophyllotoxins, Tyrosine kinase inhibitors, Vinca alkaloids | Decreased effectiveness of chemotherapy agent through induction of CYP450 induction | Avoid the use of St. John’s Wort during chemotherapy | 66 |
Abbreviations: VPA, valproic acid; trimethoprim-sulfamethoxazole (TMP/SMX); NSAIDs, non-steroidal anti-inflammatory drugs.